Steroid Refractory Acute GvHD Clinical Trial Pipeline Gains Momentum: 3+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight's, "Steroid Refractory Acute Graft Versus Host Disease Pipeline Insights 2026" Report provides comprehensive insights about 3+ companies and 4+ pipeline drugs in Steroid Refractory Acute Graft Versus Host Disease pipeline landscape. It covers the Steroid Refractory Acute Graft Versus Host Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Steroid Refractory Acute Graft Versus Host Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Dive into DelveInsight's comprehensive report today! @ https://www.delveinsight.com/sample-request/steroid-refractory-acute-graft-versus-host-disease-pipeline-insight [https://www.delveinsight.com/sample-request/steroid-refractory-acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Steroid Refractory Acute Graft Versus Host Disease Pipeline Report

*
In December 2025, Asian Institute of Gastroenterology, India announced a study is designed to explore whether the combination of infliximab and tofacitinib offers greater early clinical benefit compared to infliximab alone, tofacitinib alone for adults hospitalized with ASUC who do not respond to intravenous corticosteroids.The goal is to generate preliminary data that may inform future treatment approaches aimed at improving remission rates, accelerating mucosal healing, and reducing the need for colectomy in this high risk population.

*
DelveInsight's Steroid Refractory Acute Graft Versus Host Disease pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Steroid Refractory Acute Graft Versus Host Disease treatment.

*
The leading Steroid Refractory Acute Graft Versus Host Disease Companies such as MaaT Pharma, ReAlta Life Sciences Inc., Ironwood Pharmaceuticals, Wuhan Optics Valley Vcanbiopharma Co. Ltd., and others.

*
Promising Steroid Refractory Acute Graft Versus Host Disease Pipeline Therapies such as Ruxolitinib, Tocilizumab, MC0518, ASC930, Neihulizumab (ALTB-168), Methoxsalen, Jaktinib Hydrochloride Tablets, ALPN-101, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Steroid Refractory Acute Graft Versus Host Disease Treatment Drugs [https://www.delveinsight.com/sample-request/steroid-refractory-acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Steroid Refractory Acute Graft Versus Host Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Steroid Refractory Acute Graft Versus Host Disease Pipeline Report also highlights the unmet needs with respect to the Steroid Refractory Acute Graft Versus Host Disease.

Steroid Refractory Acute Graft Versus Host Disease Overview

Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) is a severe and life-threatening complication that can occur after allogeneic hematopoietic stem cell transplantation (HSCT). Acute GVHD develops when donor immune cells recognize the recipient's tissues as foreign and initiate an inflammatory immune response. Corticosteroids are considered the first-line therapy; however, a significant proportion of patients fail to respond adequately, leading to the classification of steroid-refractory aGVHD.

Steroid Refractory Acute Graft Versus Host Disease Emerging Drugs Profile

*
MaaT013: MaaT Pharma

MaaT013 is an innovative, first-in-class, pooled allogeneic microbiome therapeutic developed by MaaT Pharma for treating steroid-refractory acute Graft-versus-Host Disease (SR-aGVHD). This therapeutic approach involves administering a standardized, carefully screened fecal microbiota preparation derived from multiple donors, designed to restore gut microbiome diversity and modulate immune responses in patients who have failed standard steroid treatments. It is a donor-derived, standardized, high-richness, high-diversity microbiome ecosystem therapy, containing Butycore, a group of bacterial species known to produce anti-inflammatory short-chain-fatty acids. MaaT013 has received Orphan Drug Designation from FDA and EMA. Currently, the drug is in Phase III stage of its development for the treatment of Steroid refractory acute graft-versus-host disease.

*
RLS-0071: ReAlta Life Sciences, Inc.

RLS-0071 (pegtarazimod) is an innovative investigational therapeutic candidate developed by ReAlta Life Sciences, Inc. for treating Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGvHD). Based on the company's unique EPICC peptide platform, RLS-0071 features a dual-targeting mechanism designed to modulate both complement and innate inflammatory pathways, offering a novel approach to addressing this serious post-transplantation complication. The drug has received Orphan Drug Designation and Fast Track Designation from the FDA. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Steroid refractory acute graft-versus-host disease.

The Steroid Refractory Acute Graft Versus Host Disease Pipeline Report Provides Insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Steroid Refractory Acute Graft Versus Host Disease with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Steroid Refractory Acute Graft Versus Host Disease Treatment.

*
Steroid Refractory Acute Graft Versus Host Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Steroid Refractory Acute Graft Versus Host Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Steroid Refractory Acute Graft Versus Host Disease market

Access DelveInsight's detailed report now! @ New Steroid Refractory Acute Graft Versus Host Disease Drugs [https://www.delveinsight.com/sample-request/steroid-refractory-acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Steroid Refractory Acute Graft Versus Host Disease Companies

MaaT Pharma, ReAlta Life Sciences Inc., Ironwood Pharmaceuticals, Wuhan Optics Valley Vcanbiopharma Co. Ltd., and others.

Steroid Refractory Acute Graft Versus Host Disease Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Oral

*
Intravenous

*
Subcutaneous

*
Intramuscular

*
Molecule Type

Steroid Refractory Acute Graft Versus Host Disease Products have been categorized under various Molecule types such as

*
Monoclonal Antibody

*
Peptides

*
Small molecule

*
Product Type

Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Steroid Refractory Acute Graft Versus Host Disease Market Drivers and Barriers [https://www.delveinsight.com/sample-request/steroid-refractory-acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Steroid Refractory Acute Graft Versus Host Disease Pipeline Report

*
Coverage- Global

*
Steroid Refractory Acute Graft Versus Host Disease Companies- MaaT Pharma, ReAlta Life Sciences Inc., Ironwood Pharmaceuticals, Wuhan Optics Valley Vcanbiopharma Co. Ltd., and others.

*
Steroid Refractory Acute Graft Versus Host Disease Pipeline Therapies- Ruxolitinib, Tocilizumab, MC0518, ASC930, Neihulizumab (ALTB-168), Methoxsalen, Jaktinib Hydrochloride Tablets, ALPN-101, and others.

*
Steroid Refractory Acute Graft Versus Host Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

*
Steroid Refractory Acute Graft Versus Host Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight's in-depth pipeline report today! @ Steroid Refractory Acute Graft Versus Host Disease Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/steroid-refractory-acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

*
Introduction

*
Executive Summary

*
Steroid Refractory Acute Graft-Versus-Host Disease : Overview

*
Pipeline Therapeutics

*
Therapeutic Assessment

*
Steroid Refractory Acute Graft-Versus-Host Disease - DelveInsight's Analytical Perspective

*
Late Stage Products (Phase III)

*
MaaT013: MaaT Pharma

*
Mid Stage Products (Phase II)

*
RLS-0071: ReAlta Life Sciences, Inc.

*
Early Stage Products (Phase I)

*
Preclinical and Discovery Stage Products

*
Inactive Products

*
Steroid Refractory Acute Graft-Versus-Host Disease Key Companies

*
Steroid Refractory Acute Graft-Versus-Host Disease Key Products

*
Steroid Refractory Acute Graft-Versus-Host Disease - Unmet Needs

*
Steroid Refractory Acute Graft-Versus-Host Disease - Market Drivers and Barriers

*
Steroid Refractory Acute Graft-Versus-Host Disease - Future Perspectives and Conclusion

*
Steroid Refractory Acute Graft-Versus-Host Disease Analyst Views

*
Steroid Refractory Acute Graft-Versus-Host Disease Key Companies

*
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=steroid-refractory-acute-gvhd-clinical-trial-pipeline-gains-momentum-3-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/steroid-refractory-acute-graft-versus-host-disease-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.